ES2909634T3 - Compuestos y usos de los mismos para la modulación de hemoglobina - Google Patents

Compuestos y usos de los mismos para la modulación de hemoglobina Download PDF

Info

Publication number
ES2909634T3
ES2909634T3 ES14768414T ES14768414T ES2909634T3 ES 2909634 T3 ES2909634 T3 ES 2909634T3 ES 14768414 T ES14768414 T ES 14768414T ES 14768414 T ES14768414 T ES 14768414T ES 2909634 T3 ES2909634 T3 ES 2909634T3
Authority
ES
Spain
Prior art keywords
alkyl
ring
optionally substituted
compound
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14768414T
Other languages
English (en)
Spanish (es)
Inventor
Zhe Li
Qing Xu
Brian W Metcalf
Ii Gwaltney
Jason R Harris
Calvin W Yee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Global Blood Therapeutics Inc
Original Assignee
Global Blood Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51580734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2909634(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US13/815,776 external-priority patent/US9458139B2/en
Application filed by Global Blood Therapeutics Inc filed Critical Global Blood Therapeutics Inc
Application granted granted Critical
Publication of ES2909634T3 publication Critical patent/ES2909634T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES14768414T 2013-03-15 2014-03-10 Compuestos y usos de los mismos para la modulación de hemoglobina Active ES2909634T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/815,776 US9458139B2 (en) 2013-03-15 2013-03-15 Compounds and uses thereof for the modulation of hemoglobin
US201361905802P 2013-11-18 2013-11-18
PCT/US2014/022846 WO2014150289A1 (en) 2013-03-15 2014-03-10 Compounds and uses thereof for the modulation of hemoglobin

Publications (1)

Publication Number Publication Date
ES2909634T3 true ES2909634T3 (es) 2022-05-09

Family

ID=51580734

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14768414T Active ES2909634T3 (es) 2013-03-15 2014-03-10 Compuestos y usos de los mismos para la modulación de hemoglobina

Country Status (18)

Country Link
EP (1) EP2970315B1 (cg-RX-API-DMAC7.html)
JP (2) JP6401772B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150132147A (cg-RX-API-DMAC7.html)
CN (1) CN105209469A (cg-RX-API-DMAC7.html)
AP (1) AP2015008720A0 (cg-RX-API-DMAC7.html)
AU (1) AU2014237361A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015021980A2 (cg-RX-API-DMAC7.html)
CA (1) CA2902721C (cg-RX-API-DMAC7.html)
EA (1) EA201591427A1 (cg-RX-API-DMAC7.html)
ES (1) ES2909634T3 (cg-RX-API-DMAC7.html)
IL (1) IL240845A0 (cg-RX-API-DMAC7.html)
MX (1) MX388013B (cg-RX-API-DMAC7.html)
PE (1) PE20151907A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201507351PA (cg-RX-API-DMAC7.html)
TW (1) TW201518286A (cg-RX-API-DMAC7.html)
UY (1) UY35425A (cg-RX-API-DMAC7.html)
WO (1) WO2014150289A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201506390B (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2790358T3 (es) 2011-12-28 2020-10-27 Global Blood Therapeutics Inc Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular
SI3738434T1 (sl) 2011-12-28 2024-01-31 Global Blood Therapeutics, Inc. Vmesne spojine za pridobivanje substituiranih benzaldehidnih spojin in postopki njihove uporabe pri povečanju oksigenacije tkiv
EP2970196B1 (en) 2013-03-15 2020-11-25 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
SG11201507453VA (en) 2013-03-15 2015-10-29 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9981939B2 (en) 2013-03-15 2018-05-29 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
DK3102208T4 (da) 2014-02-07 2024-08-26 Global Blood Therapeutics Inc Krystallinsk polymorph af den frie base af 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyd
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CA3251507A1 (en) 2015-10-16 2025-05-21 Abbvie Inc. Use of a solid dosage form comprising (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide for treating rheumatoid arthritis
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
ES3039236T3 (en) 2015-12-04 2025-10-20 Global Blood Therapeutics Inc Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
TWI663160B (zh) 2016-05-12 2019-06-21 全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
US10787430B2 (en) 2016-06-17 2020-09-29 Fronthera U.S. Pharmaceuticals Llc Hemoglobin modifier compounds and uses thereof
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin
KR102842589B1 (ko) * 2018-11-19 2025-08-04 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈을 조정할 수 있는 2-포르밀-3-히드록시페닐옥시메틸 화합물
BR112021009057A2 (pt) 2018-11-29 2021-08-10 Pfizer Inc. pirazóis como moduladores de hemoglobina

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU190371B (en) * 1980-12-18 1986-08-28 The Wellcome Foundation Ltd,Gb Process for producing ether-type compounds and pharmaceutical compositions containing them as active agents
FR2680512B1 (fr) * 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5521202A (en) * 1993-04-07 1996-05-28 Taiho Pharmaceutical Co., Ltd. Thiazolidine derivatives and pharmaceutical compositions containing the same
CN1221417A (zh) * 1996-07-26 1999-06-30 雷迪博士研究基金会 具有抗糖尿病、降低血脂、抗高血压性能的噻唑烷二酮化合物,其制备方法及其药物组合物
US6184228B1 (en) * 1999-05-25 2001-02-06 Anadys Pharmaceuticals, Inc. Anti-sickling agents: selection methods and effective compounds
AUPQ105499A0 (en) * 1999-06-18 1999-07-08 Biota Scientific Management Pty Ltd Antiviral agents
US20030022923A1 (en) * 2001-03-01 2003-01-30 Medinox, Inc. Methods for treatment of sickle cell anemia
PT2179987E (pt) * 2002-12-04 2013-03-11 Univ Virginia Commonwealth Utilização de derivados carbaldeído heterocíclicos contra a anemia falciforme
EP1694328A4 (en) * 2003-12-02 2010-02-17 Celgene Corp METHOD AND COMPOSITIONS FOR THE TREATMENT AND SUPPLY OF HEMOGLOBINOPATHY AND ANEMIA
DE102008027574A1 (de) * 2008-06-10 2009-12-17 Merck Patent Gmbh Neue Pyrrolidinderivate als MetAP-2 Inhibitoren
TW201139406A (en) * 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers
US20120122928A1 (en) * 2010-08-11 2012-05-17 Bayer Cropscience Ag Heteroarylpiperidine and -Piperazine Derivatives as Fungicides
SI3738434T1 (sl) * 2011-12-28 2024-01-31 Global Blood Therapeutics, Inc. Vmesne spojine za pridobivanje substituiranih benzaldehidnih spojin in postopki njihove uporabe pri povečanju oksigenacije tkiv
US9981939B2 (en) * 2013-03-15 2018-05-29 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin

Also Published As

Publication number Publication date
JP2016512824A (ja) 2016-05-09
IL240845A0 (en) 2015-10-29
TW201518286A (zh) 2015-05-16
JP6401772B2 (ja) 2018-10-10
EP2970315B1 (en) 2021-09-15
PE20151907A1 (es) 2016-01-20
MX2015011509A (es) 2016-05-31
WO2014150289A1 (en) 2014-09-25
MX388013B (es) 2025-03-19
KR20150132147A (ko) 2015-11-25
EA201591427A1 (ru) 2016-01-29
CN105209469A (zh) 2015-12-30
SG11201507351PA (en) 2015-10-29
AP2015008720A0 (en) 2015-09-30
BR112015021980A2 (pt) 2017-07-18
EP2970315A1 (en) 2016-01-20
AU2014237361A1 (en) 2015-09-17
CA2902721A1 (en) 2014-09-25
ZA201506390B (en) 2017-03-29
JP2018188481A (ja) 2018-11-29
CA2902721C (en) 2021-09-14
EP2970315A4 (en) 2016-08-17
UY35425A (es) 2014-10-31

Similar Documents

Publication Publication Date Title
ES2909634T3 (es) Compuestos y usos de los mismos para la modulación de hemoglobina
US10100040B2 (en) Compounds and uses thereof for the modulation of hemoglobin
ES2852054T3 (es) Compuestos y usos de los mismos para la modulación de hemoglobina
ES2864707T3 (es) Compuestos y usos de los mismos para la modulación de la hemoglobina
ES2993155T3 (en) Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) Compounds and uses thereof for the modulation of hemoglobin
US20190300477A1 (en) Compounds and uses thereof for the modulation of hemoglobin
OA17478A (en) Compounds and uses thereof for the modulation of hemoglobin.
OA17480A (en) Compounds and uses thereof for the modulation of hemoglobin.